Skip to content

Home
About Us
Office
E-Library
Research Support
Blog
Donation
Contact Us

Home
About Us
Office
E-Library
Research Support
Blog
Donation
Contact Us

April 10, 2025

New Releases from NCBI BookshelfCabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine.Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfEmpagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction.Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfGlofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments .Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments .

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfLutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments.Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfDurvalumab (endometrial cancer, pMMR): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A24-86 [Internet].Durvalumab (endometrial cancer, pMMR): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A24-86 [Internet].

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfRitlecitinib for treating severe alopecia areata in people 12 years and over.Ritlecitinib for treating severe alopecia areata in people 12 years and over.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfAxicabtagene ciloleucel (DLBCL and HGBL, second line): Benefit assessment according to §35a SGB V, (expiry of the decision): IQWiG Reports – Commission No. A24-71 [Internet].Axicabtagene ciloleucel (DLBCL and HGBL, second line): Benefit assessment according to §35a SGB V, (expiry of the decision): IQWiG Reports – Commission No. A24-71 [Internet].

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfDecitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal).Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal).

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfMirikizumab for treating moderately to severely active ulcerative colitis.Mirikizumab for treating moderately to severely active ulcerative colitis.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfBaricitinib for treating severe alopecia areata.Baricitinib for treating severe alopecia areata.

Leave a Comment / Uncategorized / admin

Post Content

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

Registration No: 771800548 Contact Number : +91-8249516996

Publication
Skill Development
Blog Writing

Research
Awareness Camp
Digital Research

Ngo Darpan
Service
Donation

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Term and Condition
Privacy Policy
Disclaimer

Scroll to Top